Farmacologia_FMABC_News

17/02/2026

Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease - An Open-Label, Multicenter Randomized Clinical Trial

This randomized clinical trial examines the safety and efficacy of guideline-recommended treatments for patients with heart failure with reduced ejection fraction caused by Chagas disease.

15/02/2026

The gut-lung axis in COPD: immunomodulatory roles of gut microbiota and novel therapeutic strategies

https://pmc.ncbi.nlm.nih.gov/articles/PMC12886472/?fbclid=IwdGRleAP_B0JleHRuA2FlbQIxMQBzcnRjBmFwcF9pZAo2NjI4NTY4Mzc5AAEeBGWD5N1ayh6c0qF2f6wKKROjxq2tPRJLZh0JF530yMpoeoQ3_lW-xMiraN4_aem_SE6ixgjHaPA95Y3QsOjibQ

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disorder characterized by persistent airflow limitation and systemic inflammation, with accumulating evidence implicating gut microbiota dysbiosis as a key modulator of ...

06/02/2026

Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial

Implementation of an AI stethoscope in routine primary care did not significantly increase detection of heart failure or increase community-based diagnosis after 12 months of implementation. AI stethoscope use was independently associated with significantly higher detection rates of heart failure, a...

25/01/2026

Impact of commonly used drugs on the composition and metabolic function of the gut microbiota

Here, via a metagenomics analysis of population-based and disease cohorts, Vich Vila et al. study the impact of 41 commonly used medications on the taxonomic structures, metabolic potential and resistome of the gut microbiome, underscoring the importance of correcting for multiple drug use in m...

03/01/2026

FDA approved drugs in 2025

03/01/2026

Developments in Pharmacotherapy for Obstructive Sleep Apnoea: Unlocking the Potential for Targeted Treatment

Obstructive sleep apnoea (OSA) is a common, chronic respiratory disorder associated with major co-morbidity and adverse safety consequences. New research has highlighted the heterogeneity of OSA pathogenesis and the importance of non-anatomical contributors beyond the primary cause—impaired pharyn...

27/12/2025

Development of Antiepileptic Drugs throughout History: From Serendipity to Artificial Intelligence

https://www.mdpi.com/2227-9059/11/6/1632?fbclid=IwdGRleAO84UtleHRuA2FlbQEwAGFkaWQBqyvWN2hVQHNydGMGYXBwX2lkCjY2Mjg1NjgzNzkAAR7QOinViNvWDUfhbzZtCd9pjchVhuwUq5II4aYbL8YICS8hXyfUr5IlNBpZuw_aem_fsbSGYsPAnBGTh69tNjKTg&utm_medium=paid&utm_source=fb&utm_id=120214559565730272&utm_content=120237219461580272&utm_term=120229000083060272&utm_campaign=120214559565730272

This article provides a comprehensive narrative review of the history of antiepileptic drugs (AEDs) and their development over time.

24/12/2025

FDA Update: Agency Approves Etripamil Nasal Spray to Treat Paroxysmal Supraventricular Tachycardia

FDA Update: Agency Approves Etripamil Nasal Spray to Treat Paroxysmal Supraventricular Tachycardia Dec 16, 2025 ACC News Story Print Font Size A A A The U.S. Food and Drug Administration (FDA) has approved Cardamyst™ (etripamil) nasal spray to treat adults with paroxysmal supraventricular tachycar...

07/12/2025

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial

Eloralintide produced clinically meaningful, dose-dependent reductions in bodyweight over 48 weeks and was generally well tolerated, supporting eloralintide's potential use for obesity treatment.

23/11/2025

Aldosterone Synthase Inhibitors for Resistant Hypertension: Pharmacological Insights – A Systematic Review

Background Resistant hypertension (RHT) is a challenging clinical condition characterized by persistently elevated blood pressure despite adherence to lifestyle modifications and the use of at least three antihypertensive agents, including a high-dose diuretic. RHT is a heterogeneous condition, infl...

23/11/2025

Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms

Vasomotor symptoms (VMS) are considered the cardinal symptoms of menopause, affecting up to 80% of American women at some point during the menopausal transition. VMS, particularly if they are moderate to severe, frequent, or cause sleep disturbances, can have a negative impact on a woman’s quality...

22/11/2025

Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial

In participants with chronic kidney disease at increased risk of disease progression, a fixed dose combination of balcinrenone and dapagliflozin was superior to dapagliflozin alone in reducing albuminuria. Balcinrenone plus dapagliflozin was well tolerated, effects on potassium were minor, and no un...